PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26405593-0	2015	A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.	iph4102	72-79	TSPY like 2	Homo sapiens	35-39	
25361998-2	2014	In this study, we report the development of IPH4102, a humanized monoclonal antibody that targets the immune receptor KIR3DL2, which is widely expressed on CTCL cells but few normal immune cells.	iph4102	44-51	TSPY like 2	Homo sapiens	156-160	
25361998-3	2014	Potent antitumor properties of IPH4102 were documented in allogeneic human CTCL cells and a mouse model of KIR3DL2(+) disease.	iph4102	31-38	TSPY like 2	Homo sapiens	75-79	
25361998-8	2014	Together, our results offer preclinical proof of concept for the clinical development of IPH4102 to treat patients with advanced CTCL.	iph4102	89-96	TSPY like 2	Homo sapiens	129-133